Nobias Therapeutics is a biotechnology company that develops small-molecule drugs for pediatric disorders associated with genetic mutations. Its product candidate NB-001 (fasoracetam) is a non-stimulant acting on metabotropic glutamate receptors for neuropsychiatric symptoms in 22q11.2 deletion syndrome. The company serves pediatric patients with genetically defined disorders.